HbA1c Reduction
HbA1c (glycated haemoglobin) is the primary clinical measure of long-term blood sugar control in Type 2 diabetes. It reflects average blood glucose over the preceding 2–3 months and is expressed as a percentage (or in mmol/mol in some countries). A reduction in HbA1c of ≥0.5% is considered clinically meaningful for microvascular risk reduction; reductions of ≥1% are substantial. Tirzepatide’s HbA1c reductions in the SURPASS Phase 3 programme are among the largest consistently reported for any T2D drug.
Ontology HbA1c Reduction [measured_by] SURPASS-1 HbA1c Reduction [measured_by] SURPASS-2 HbA1c Reduction [measured_by] SURPASS-4 HbA1c Reduction [measured_by] SURPASS-6 HbA1c Reduction [associated_with] Tirzepatide HbA1c Reduction [relates] Type 2 Diabetes HbA1c Reduction [relates] Insulin-Use Reduction HbA1c Reduction [relates] Weight Loss in T2D
Evidence Summary
Best-supported finding: Tirzepatide (5, 10, 15 mg once weekly) produces dose-dependent HbA1c reductions in T2D across all treatment stages, consistently superior to placebo, semaglutide 1 mg, and basal insulin analogues.
Absolute numbers by trial:
| Trial | Population | Tirzepatide | Comparator | Difference |
|---|---|---|---|---|
| SURPASS-1 (40 wk) | Monotherapy, mean HbA1c 7.9% | −1.87%/−1.89%/−2.07% (5/10/15mg) | +0.04% (placebo) | −1.91%/−1.93%/−2.11% |
| SURPASS-2 (40 wk) | On metformin, HbA1c 8.28% | −2.01%/−2.24%/−2.30% (5/10/15mg) | −1.86% (semaglutide 1mg) | −0.15%/−0.39%/−0.45% |
| SURPASS-4 (52 wk) | High CV risk, oral agents, HbA1c 8.52% | −2.43%/−2.58% (10/15mg) | −1.44% (glargine) | −0.99%/−1.14% |
| SURPASS-6 (52 wk) | On basal insulin, HbA1c 8.8% | −2.1% (pooled) | −1.1% (lispro) | −0.98% |
Target attainment (SURPASS-1):
- HbA1c <7.0%: 87–92% (tirzepatide) vs 20% (placebo)
- HbA1c ≤6.5%: 81–86% vs 10%
- HbA1c <5.7% (near-normal): 31–52% vs 1%
Meta-analysis pooled estimates (Karagiannis et al., Diabetologia 2022, 7 trials, 6609 participants):
- vs placebo: −1.62% to −2.06% (dose-dependent)
- vs GLP-1 RAs: −0.29% to −0.92%
- vs basal insulin: −0.70% to −1.09%
Time period: Effects observed at 40–52 weeks; no long-term (>2 year) data from dedicated T2D glycaemia studies in primary SURPASS trials
Confidence level: High for short-term (40–52 week) trials; moderate for interpretation in patients with advanced T2D, very high baseline HbA1c, or significant beta-cell failure; low for patients aged 70+ or with frailty
Main caveats:
- All trials funded by Eli Lilly; many principal investigators had financial relationships with manufacturer
- Meta-analysis limited to ~2-year data maximum; no long-term glycaemic trajectory beyond 104 weeks
- Most participants were overweight/obese on metformin background — may not generalise to lean T2D or severe insulin deficiency
- HbA1c reduction partially mediated by weight loss; weight-independent component confirmed but modest in post-hoc analysis
Connections
- SURPASS-1 — measured_by, [2021], source: PMID 34186022
- SURPASS-2 — measured_by, [2021], source: PMID 34170647
- SURPASS-4 — measured_by, [2021], source: PMID 34672967
- SURPASS-6 — measured_by, [2023], source: PMID 37786396
- Tirzepatide — associated_with, [2021–2023]
- Weight Loss in T2D — confounded_by (partial), [2021–2023], source: PMID 37246796
- Insulin-Use Reduction — relates, [2021–2023]